Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Launches DDAVP Generic With 180-Day Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves Barr’s ANDA for Sanofi-Aventis’ bed-wetting therapy DDAVP. Approval comes five months after Barr prevailed in a patent dispute with DDAVP manufacturer Ferring.

You may also be interested in...



FDA Chief Counsel Bradshaw's "Practical" Approach Applauded By Barr

Barr CEO Bruce Downey is praising FDA Chief Counsel Sheldon Bradshaw's attitude towards issues affecting the generic drug industry

FDA Chief Counsel Bradshaw's "Practical" Approach Applauded By Barr

Barr CEO Bruce Downey is praising FDA Chief Counsel Sheldon Bradshaw's attitude towards issues affecting the generic drug industry

Barr Says Citizen Petition Is Remaining Obstacle To DDAVP Generic Approval

Federal court ruling that Sanofi-Aventis patents on desmopressin tablets are invalid and not infringed "effectively ends" 30-month stay of approval on Barr's ANDA for the bed-wetting therapy, generic firm says. A pending citizen petition seeks to establish specific bioequivalence requirements for DDAVP generics.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel